Login / Signup

Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.

Christian FriedrichKlaus FranckeIsabella GashawChristian ScheeransStefan KleinLueder FelsJaclyn Ann SmithThomas HummelAlyn Hugh Morice
Published in: Clinical pharmacokinetics (2022)
Clinicaltrials.gov: NCT03310645 (initial registration: 16 October, 2017).
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • phase iii
  • study protocol
  • phase ii
  • open label